EFFECT OF AN ALDOSE REDUCTASE INHIBITOR, SNK-860, ON DEFICITS IN THE ELECTRORETINOGRAM OF DIABETIC RATS

被引：11

作者：

HOTTA, N ^{[1
]}

KOH, N ^{[1
]}

SAKAKIBARA, F ^{[1
]}

NAKAMURA, J ^{[1
]}

HAMADA, Y ^{[1
]}

NARUSE, K ^{[1
]}

SASAKI, H ^{[1
]}

MIZUNO, K ^{[1
]}

MATSUBARA, A ^{[1
]}

KAKUTA, H ^{[1
]}

FUKASAWA, H ^{[1
]}

SAKAMOTO, N ^{[1
]}

机构：

[1] SANWA KAGAKU KENKYUSHO CO LTD,DEPT PHARMACOL,HOKUSEI,MIE,JAPAN

来源：

EXPERIMENTAL PHYSIOLOGY | 1995年 / 80卷 / 06期

关键词：

D O I：

10.1113/expphysiol.1995.sp003909

中图分类号：

Q4 [生理学];

学科分类号：

071003 ;

摘要：

To determine the effect of an aldose reductase inhibitor, SNK-860, on the worsening of the electroretinogram (ERG) during a diabetic state, rats with streptozotocin-induced diabetes were administered SNK-860 (1 or 4 mg kg(-1) orally) daily for 4 weeks. The effectiveness of SNK-860 in prolonging the peak latencies of oscillatory potentials in the b-wave of the electroretinogram of diabetic rats varied between these different waveform components (designated O-1, O-2 and O-3). SNK-860 (4 mg kg(-1) day(-1)) either completely or partially prevented the prolonged peak latencies at O-1 and Sigma(O-1 + O-2 + O-3). The drug failed to shorten the latency of the O-2 and O-3 components, and produced only a modest reduction in retinal levels of sorbitol and fructose, with no increase in myo-inositol. There was a significant correlation between the state of the ERG (components O-1 and Sigma(O-1 + O-2 + O-3)) and the retinal levels of sorbitol and fructose (P < 0.01), but not of myo-inositol. It is concluded that a better understanding of the mechanism by which SNK-860 acts may provide new insight into the pathogenesis of hyperglycaemic retinal dysfunction and help to establish effective therapy for diabetic retinopathy.

引用

页码：981 / 989

页数：9

共 43 条

[1] LOCALIZATION OF ALDOSE REDUCTASE IN THE HUMAN-EYE [J].

AKAGI, Y ;

YAJIMA, Y ;

KADOR, PF ;

KUWABARA, T ;

KINOSHITA, JH .

DIABETES, 1984, 33 (06) :562-566

[2]

ALGVERE P, 1968, ACTA OPHTHALMOL, V46, P993

[3]

Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1196

[4]

Bergmeyer H. U., 1974, METHOD ENZYMAT AN, V3, P1323

[5]

BERNT E, 1974, METHOD ENZYMAT AN, V3, P1304

[6]

DENEAULT LG, 1980, DOC OPHTHALMOL, V23, P67

[7]

FUJIMOTO M, 1981, BRAIN RES, V204, P51, DOI 10.1016/0006-8993(81)90651-X

[8]

GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609

[9]

GILLON KRW, 1983, DIABETOLOGIA, V25, P365

[10]

GREENE DA, 1987, NEW ENGL J MED, V316, P599

← 1 2 3 4 5 →